Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Mutagenesis ; 16(5): 423-30, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11507242

ABSTRACT

To investigate the relationship between oncogene activation and induction of micronuclei by a new non-peptidic mimetic farnesyltransferase inhibitor, RPR-115135, two isogenic cell lines, human colon cancer line HCT-116, which harbors a K-ras mutation, and spontaneously immortalized human breast epithelial cell line MCF-10A, were utilized. HCT-116 cells were transfected with an empty control pCMV vector (clone CMV-2) or with a dominant negative mutated p53 transgene (clone Mu-p53-2) to disrupt p53 function. In both clones RPR-115135 induced a significant increase in the frequency of micronucleation at concentrations that did not affect cell membrane integrity. RPR-115135 produced a significant increase in the ratio of CREST+ to CREST- micronuclei. MCF-10A cells were stably transfected with either c-Ha-ras or c-erbB-2 or both H-ras + c-erbB-2. No induction of micronuclei was observed. No induction of micronuclei was reported in human lymphocytes and in primary spinal cells obtained from 7-day chick embryos. In conclusion, RPR-115135 acts as an aneugenic agent in a complex manner, dependent upon the complement of mutations in cell regulatory genes in tumour cells and this activity may be independent of ras genotype.


Subject(s)
Alkyl and Aryl Transferases/antagonists & inhibitors , Enzyme Inhibitors/toxicity , Indoles/toxicity , Micronuclei, Chromosome-Defective/drug effects , Micronuclei, Chromosome-Defective/enzymology , Mutagenesis/physiology , Animals , Chick Embryo , Drug Resistance, Neoplasm/genetics , Farnesyltranstransferase , Gene Expression Regulation, Neoplastic/drug effects , Humans , Micronuclei, Chromosome-Defective/metabolism , Molecular Mimicry , Mutagenesis/genetics , Time Factors , Tumor Cells, Cultured
2.
Exp Cell Res ; 221(1): 27-40, 1995 Nov.
Article in English | MEDLINE | ID: mdl-7589253

ABSTRACT

In this study we focused our attention on the behavior of four nuclear matrix proteins during the various stages of apoptosis in the HL-60 cell line exposed to the DNA topoisomerase I inhibitor, camptothecin. We have examined the following antigens by immunocytochemical techniques: (i) the 180-kDa nucleolar isoform of DNA topoisomerase II; (ii) a 126-kDa polypeptide of nuclear bodies; (iii) a 125-kDa protein; and (iv) a 160-kDa polypeptide which are known to be components of the matrix inner network. Indirect immunofluorescence experiments were performed to follow these nuclear matrix antigens during apoptosis. Moreover, the ultrastructural localization of both 125- and 160-kDa proteins was investigated by electron microscope immunocytochemistry with gold-conjugated secondary antibodies. While the antibody to the nucleolar isoform of DNA topoisomerase II gave a fluorescent pattern that was well-maintained until the late phases of apoptosis, the other three nuclear antigens showed marked modifications in their distribution. A common feature, particularly evident for 125- and 160-kDa proteins, was their absence from cap-shaped chromatin marginations, whereas they were present in the areas of remaining decondensed chromatin. The 126-kDa polypeptide concentrated progressively in an irregular mass at the opposite side of the crescentic caps and then broke up in fine spots. The 125- and 160-kDa proteins localized in the nucleolus and precisely within certain granules which are known to appear in the nucleolar area after camptothecin administration. These results show that, in addition to the well-known chromatin changes, nuclear organization undergoes other rearrangements during the apoptotic process.


Subject(s)
Antineoplastic Agents, Phytogenic/pharmacology , Apoptosis/physiology , Autoantigens/metabolism , Camptothecin/pharmacology , HL-60 Cells/cytology , Nuclear Proteins/immunology , Nuclear Proteins/metabolism , Antigens, Nuclear , Apoptosis/drug effects , DNA Topoisomerases, Type II/immunology , DNA Topoisomerases, Type II/metabolism , Fluorescent Antibody Technique, Indirect , HL-60 Cells/ultrastructure , Humans , Immunohistochemistry , Isoenzymes/immunology , Isoenzymes/metabolism , Micronuclei, Chromosome-Defective/enzymology , Microscopy, Electron , Nuclear Matrix/enzymology
SELECTION OF CITATIONS
SEARCH DETAIL
...